Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma

Theodore A. Braich; Sydney E. Salmon; Aurelia Robertone; David S. Alberts; Stephen E. Jones; Thomas P. Miller; Harinder S. Garewal

doi:10.1007/BF00179595

Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma

Theodore A. Braich, Sydney E. Salmon, Aurelia Robertone, David S. Alberts, Stephen E. Jones, Thomas P. Miller, Harinder S. Garewal

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

A phase II trial of esorubicin (4′ deoxydoxorubicin) was performed in patients with cancers of the breast, colon, kidney, lung and melanoma. Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. No objective responses (complete or partial) were seen in patients with colon cancer (18 patients), lung cancer (12 patients), renal cell cancer (12 patients) and melanoma (18 patients). Myelosuppression was the most significant toxicity encountered with granulocytopenia (neutrophils < 1,000) observed in 38% of patients. As discussed, we feel that further investigation of esorubicin in anthracyclinesensitive tumors is warranted.

Original language	English (US)
Pages (from-to)	269-274
Number of pages	6
Journal	Investigational New Drugs
Volume	4
Issue number	3
DOIs	https://doi.org/10.1007/BF00179595
State	Published - Sep 1986

Keywords

esorubicin
phase II

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00179595

Cite this

@article{b759fb23517f4383b148dca9a370bee2,

title = "Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma",

abstract = "A phase II trial of esorubicin (4′ deoxydoxorubicin) was performed in patients with cancers of the breast, colon, kidney, lung and melanoma. Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. No objective responses (complete or partial) were seen in patients with colon cancer (18 patients), lung cancer (12 patients), renal cell cancer (12 patients) and melanoma (18 patients). Myelosuppression was the most significant toxicity encountered with granulocytopenia (neutrophils < 1,000) observed in 38% of patients. As discussed, we feel that further investigation of esorubicin in anthracyclinesensitive tumors is warranted.",

keywords = "esorubicin, phase II",

author = "Braich, {Theodore A.} and Salmon, {Sydney E.} and Aurelia Robertone and Alberts, {David S.} and Jones, {Stephen E.} and Miller, {Thomas P.} and Garewal, {Harinder S.}",

year = "1986",

month = sep,

doi = "10.1007/BF00179595",

language = "English (US)",

volume = "4",

pages = "269--274",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma

AU - Braich, Theodore A.

AU - Salmon, Sydney E.

AU - Robertone, Aurelia

AU - Alberts, David S.

AU - Jones, Stephen E.

AU - Miller, Thomas P.

AU - Garewal, Harinder S.

PY - 1986/9

Y1 - 1986/9

N2 - A phase II trial of esorubicin (4′ deoxydoxorubicin) was performed in patients with cancers of the breast, colon, kidney, lung and melanoma. Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. No objective responses (complete or partial) were seen in patients with colon cancer (18 patients), lung cancer (12 patients), renal cell cancer (12 patients) and melanoma (18 patients). Myelosuppression was the most significant toxicity encountered with granulocytopenia (neutrophils < 1,000) observed in 38% of patients. As discussed, we feel that further investigation of esorubicin in anthracyclinesensitive tumors is warranted.

AB - A phase II trial of esorubicin (4′ deoxydoxorubicin) was performed in patients with cancers of the breast, colon, kidney, lung and melanoma. Two partial responses were observed out of 16 patients with breast cancer treated with esorubicin. No objective responses (complete or partial) were seen in patients with colon cancer (18 patients), lung cancer (12 patients), renal cell cancer (12 patients) and melanoma (18 patients). Myelosuppression was the most significant toxicity encountered with granulocytopenia (neutrophils < 1,000) observed in 38% of patients. As discussed, we feel that further investigation of esorubicin in anthracyclinesensitive tumors is warranted.

KW - esorubicin

KW - phase II

UR - http://www.scopus.com/inward/record.url?scp=0023038013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023038013&partnerID=8YFLogxK

U2 - 10.1007/BF00179595

DO - 10.1007/BF00179595

M3 - Article

C2 - 3818231

AN - SCOPUS:0023038013

SN - 0167-6997

VL - 4

SP - 269

EP - 274

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this